跳至主要内容
临床试验/NCT00186680
NCT00186680已完成1 期

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Stanford University2 个研究点 分布在 1 个国家目标入组 99 人开始时间: 1996年9月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
99
试验地点
2
主要终点
Feasibility and safety

研究概览

简要总结

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

详细描述

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • stage IV breast cancer
  • primary breast cancer does not express CD34+
  • adequate organ function
  • no evidence of active infection

排除标准

  • chemotherapy within 4 weeks
  • CNS disease

结局指标

主要结局

Feasibility and safety

次要结局

  • efficiency of mobilization
  • tumor contamination

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验